transplantologiyaТрансплантологияTransplantologiya. The Russian Journal of Transplantation2074-05062542-0909IPO Association of Transplantologists10.23873/2074-0506-2010-0-3-4-18-22transplantologiya-289Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL INVESTIGATIONSВакцинация против вирусного гепатита B пациентов, перенесших трансплантацию печени по причинам, не связанным с гепатитом BVaccination against viral hepatitis B in patients undergoing liver transplantation for hepatitis B-unassociated causesСюткинВ. Е.SyutkinV. E.

Владимир Евгениевич Сюткин

vsyutkin@rambler.ruСалиенкоА. А.SaliyenkoA. A.СюткинаД. Е.SyutkinaD. E.ЧжаоА. В.ChzhaoA. V.Московский центр трансплантации печени НИИ скорой помощи им. Н.В. СклифосовскогоРоссияMoscow Liver Transplantation Center of N.V. Sklifosovsky Research Institute of Emergency CareRussian Federation20101708201803-41822Copyright © Сюткин В.Е., Салиенко А.А., Сюткина Д.Е., Чжао А.В., 20182018Сюткин В.Е., Салиенко А.А., Сюткина Д.Е., Чжао А.В.Syutkin V.E., Saliyenko A.A., Syutkina D.E., Chzhao A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jtransplantologiya.ru/jour/article/view/289

Цель работы – сравнение эффективности вакцинации против вирусного гепатита В (HBV) в группах больных, перенесших ортотопическую трансплатацию печени (ОТП) по причинам, этиологически не связанным с HBV, с использованием гранулоцитарно-макрофагального колониестимулирующего фактора (ГМКСФ) в качестве адъюванта и без адъювантов.

Материалы и методы

Материалы и методы. Вакцинация против HBV проводилась 18 больным, перенесшим ОТП в связи с заболеваниями печени, этиологически не связанными с инфекцией HBV. Девять пациентов получали двойные дозы вакцины по схеме 0, 1 и 2 мес с адъювантом (молграмостим). Группу сравнения составили 9 больных, получавших двойные дозы вакцины без адъюванта.

Результаты

Результаты. В группе больных, вакцинированных по схеме с адъювантом, у 4 пациентов (44,4%) наблюдался значительный иммунный ответ (анти-HBs > 200 мМЕ/мл). Ни у одного пациента из группы сравнения такого ответа не отмечено (p=0,037).

Выводы

Выводы. Применение молграмостима в качестве адъюванта при вакцинации против HBV больных, перенесших ОТП, увеличивает ее эффективность.

To study efficiency of molgramostim as an adjuvant in HBV vaccination we randomized 18 pts after OLT due to non-HBV causes. Nine pts received GM-CSF (150 mcg of sc 24 h before 1st dose of vaccine). Other 9 pts received only vaccine. Both groups of pts did not differ in sex, age, immunosuppression and received vaccine in double doses (40 mcg im) by similar way (0, 1 and 2 Mo). Anti-HBs titers were estimated in 3 Mo after the last dose of vaccine. High anti-HBs titer (>200 mME/ml) achieved 4 pts (44%) from the GM-CSF group and nobody from the control group (p=0.037) No serious adverse effects occurred. Conclusion: GM-CSF may be useful as an adjuvant in HBV vaccination after OLT.

вакцинациягепатит Вортотопическая трансплантация печенимолграмостимгранулоцитарномакрофагальный колониестимулирующий факторGM-CSFHBVvaccinationliver transplantationmolgramostimReferencesRoche B., Samuel D., Gigou M. et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997;26(3):517–26.Roche B., Samuel D., Gigou M. et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997;26(3):517–26.Fabia R., Levy M.F., Crippin J. et al. De novo hepatitis B infection after liver transplantation: sources of disease, incidence and impact. Liver Transpl Surg 1998;4(2):119–27.Fabia R., Levy M.F., Crippin J. et al. De novo hepatitis B infection after liver transplantation: sources of disease, incidence and impact. Liver Transpl Surg 1998;4(2):119–27.Su W.J., Ho M.C., Ni Y.H. et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009;48(2):203–8.Su W.J., Ho M.C., Ni Y.H. et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009;48(2):203–8.Cholongitas E., Papatheodoridis G.V., Burroughs A.K. Liver grafts from antihepatitis B core positive donors: A systematic review. J of Hepatol 2010;52(2):272–9.Cholongitas E., Papatheodoridis G.V., Burroughs A.K. Liver grafts from antihepatitis B core positive donors: A systematic review. J of Hepatol 2010;52(2):272–9.Barcena R., Moraleda G., Moreno J. et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol 2006;12(13):2070–4.Barcena R., Moraleda G., Moreno J. et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol 2006;12(13):2070–4.Roque-Afonso A.M., Feray C., Samuel D. et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002;50(1):95–9.Roque-Afonso A.M., Feray C., Samuel D. et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002;50(1):95–9.Loinaz C., de Juanes J.R., Gonzales E.M. et al. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 1997;44(13): 235–8.Loinaz C., de Juanes J.R., Gonzales E.M. et al. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 1997;44(13): 235–8.Tarr P.E., Lin R., Mueller E.A. et al. Evaluation of tolerability and antibody response after recombinant human granulocyte colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine 1996;14(13):1199–204.Tarr P.E., Lin R., Mueller E.A. et al. Evaluation of tolerability and antibody response after recombinant human granulocyte colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine 1996;14(13):1199–204.Hasan M.S., Agosti J.M., Reynolds K.K. et al. Granulocyte macrophage colony stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. J Infect Dis 1999;180(6):2023–6.Hasan M.S., Agosti J.M., Reynolds K.K. et al. Granulocyte macrophage colony stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. J Infect Dis 1999;180(6):2023–6.Fabrizi F., Ganesha S.V., Dixit V., Martin P. Meta-analysis: the adjuvant role of granulocyte-macrophage colony-stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther 2006;24(5):789–96.Fabrizi F., Ganesha S.V., Dixit V., Martin P. Meta-analysis: the adjuvant role of granulocyte-macrophage colony-stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther 2006;24(5):789–96.Sasaki M.G., Foccacia R., de MessiasReason I.J. Efficacy of granulocytemacrophage colony-stimulating factor (GMCSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003;21(31):4545–9.Sasaki M.G., Foccacia R., de MessiasReason I.J. Efficacy of granulocytemacrophage colony-stimulating factor (GMCSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003;21(31):4545–9.Martin P., Friedman L.S. Chronic viral hepatitis and the management of chronic renal failure. Kidney Int 1995;47(5): 1231–41.Martin P., Friedman L.S. Chronic viral hepatitis and the management of chronic renal failure. Kidney Int 1995;47(5): 1231–41.Cornberg M., Protzer U., Dollinger M.M. et al. Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virus-(HBV-) Infection- “Upgrade” der Leitlinie, AWMF-RegisterNr.:021/011. Z Gastroenterol 2007; 45:525–74.Cornberg M., Protzer U., Dollinger M.M. et al. Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virus-(HBV-) Infection- “Upgrade” der Leitlinie, AWMF-RegisterNr.:021/011. Z Gastroenterol 2007; 45:525–74.Cornberg M., Protzer U., Dollinger M.M. et al. The German guideline for the management of hepatitis B virus infection: short version. J Viral Hepatitis 2008; 15(suppl 1):1–20.Cornberg M., Protzer U., Dollinger M.M. et al. The German guideline for the management of hepatitis B virus infection: short version. J Viral Hepatitis 2008; 15(suppl 1):1–20.Sanchez-Fueyo A., Rimola A., Grande L. et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31(2):496–501.Sanchez-Fueyo A., Rimola A., Grande L. et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31(2):496–501.Angelico M., Di Paolo D., Trinito M.O. et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002;35(1):176–81.Angelico M., Di Paolo D., Trinito M.O. et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002;35(1):176–81.Di Paolo D., Lenci I., Trinito M.O. et al. Extended double-dosage HBV vaccination after liver transplantation is ineffective in the absence of lamivudine and prior wash-out of human hepatitis B immunoglobulins. Dig Liver Dis 2006;38(10):749–54.Di Paolo D., Lenci I., Trinito M.O. et al. Extended double-dosage HBV vaccination after liver transplantation is ineffective in the absence of lamivudine and prior wash-out of human hepatitis B immunoglobulins. Dig Liver Dis 2006;38(10):749–54.Karasu Z., Ozacar T., Akarca U. et al. HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. J Viral Hepat 2005;12(2):212–5.Karasu Z., Ozacar T., Akarca U. et al. HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. J Viral Hepat 2005;12(2):212–5.Yamashiki N., Sugawara Y., Tamura S. et al. Double-dose double-phase use of second generation hepatitis B virus vaccine in patients after living donor liver transplantation: Not an effective measure in transplant recipients. Hepatol Res 2009;39(1):7–13.Yamashiki N., Sugawara Y., Tamura S. et al. Double-dose double-phase use of second generation hepatitis B virus vaccine in patients after living donor liver transplantation: Not an effective measure in transplant recipients. Hepatol Res 2009;39(1):7–13.Rosenau J., Hooman N., Hadem J. et al. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 2007;13(3):367–73.Rosenau J., Hooman N., Hadem J. et al. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 2007;13(3):367–73.Merli M., Nicolini G., Attili F.A. et al. Failure of hepatitis B vaccination to induce either humoral or cellular immune response after liver transplantation for hepatitis B related cirrhosis. J Hepatol 2005; 43(6):1089–90.Merli M., Nicolini G., Attili F.A. et al. Failure of hepatitis B vaccination to induce either humoral or cellular immune response after liver transplantation for hepatitis B related cirrhosis. J Hepatol 2005; 43(6):1089–90.Soejima Y., Ikegami T., Taketomi A. et al. Hepatitis B vaccination after living donor liver transplantation. Liver Int 2007;27(7):977–82.Soejima Y., Ikegami T., Taketomi A. et al. Hepatitis B vaccination after living donor liver transplantation. Liver Int 2007;27(7):977–82.Park J.B., Kwon C.H., Lee K.W. et al. Hepatitis B virus vaccine switch program for prevention of de novo hepatitis B virus infection in pediatric patients. Transpl Int 2008;21(4):346–52.Park J.B., Kwon C.H., Lee K.W. et al. Hepatitis B virus vaccine switch program for prevention of de novo hepatitis B virus infection in pediatric patients. Transpl Int 2008;21(4):346–52.Kwon C.H., Suh K.S., Yi N.J. et al. Longterm protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation. Pediatr Transplant 2006;10(4):479–86.Kwon C.H., Suh K.S., Yi N.J. et al. Longterm protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation. Pediatr Transplant 2006;10(4):479–86.McMahon B.J., Parkinson A.J., Helminiak C. et al. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. Gastroenterology 1992;103(2):590–4.McMahon B.J., Parkinson A.J., Helminiak C. et al. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. Gastroenterology 1992;103(2):590–4.Lo C.M., Lau G.K., Chan S.C. et al. Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant 2007;7(2):434–9.Lo C.M., Lau G.K., Chan S.C. et al. Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant 2007;7(2):434–9.Bienzle U., Gunther M., Neuhaus R. et al. ful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transpl 2002;8(6):562–4.Bienzle U., Gunther M., Neuhaus R. et al. ful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transpl 2002;8(6):562–4.Starkel P., Stoffel M., Lerut J. et al. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBVinfected liver graft recipients. Liver Transpl 2005;11(10):1228–34.Starkel P., Stoffel M., Lerut J. et al. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBVinfected liver graft recipients. Liver Transpl 2005;11(10):1228–34.Vandepapeliere P., Lau G.K., LerouxRoels G. et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of coadministration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007;25(suppl 1):8585–97.Vandepapeliere P., Lau G.K., LerouxRoels G. et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of coadministration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007;25(suppl 1):8585–97.Bienzle U., Gunther M., Neuhaus R. et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003;38(4):811–9.Bienzle U., Gunther M., Neuhaus R. et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003;38(4):811–9.Bauer T., Gunther M., Bienzle U. et al. Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAgspecific regulatory T cells. Liver Transpl 2007;13(3):434–42.Bauer T., Gunther M., Bienzle U. et al. Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAgspecific regulatory T cells. Liver Transpl 2007;13(3):434–42.

The authors declare that there are no conflicts of interest present.